DVA
DaVita Inc.
September 17, 2026 · market open
- Rarity
- 1.85
- Peak move
- −5.96%
- Float cap
- $12.6B
DaVita Inc. is a healthcare provider focused on kidney care. It provides dialysis and related laboratory services to patients with chronic kidney failure and end-stage kidney disease in the United States and internationally, and offers integrated care and disease management to patients under risk-based and other value-based arrangements.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 0 from SEC or newswire · 0 timed with the movecustomer_lossDaVita Ecuador sent a Sept 14, 2026 letter to Ecuador's health and finance ministries demanding $121 million in unpaid MSP obligations for 3,850 MSP-referred dialysis patients across 28 centers, with a Sept 30 payment-plan deadline before a forced transition back to the public system starting Oct 3 with Farmadial Balzar.
peer_disclosureDaVita's expanded value-based care agreement with Humana covers more than 10,000 Medicare Advantage members with chronic kidney disease stages 3B-5 through DaVita Integrated Kidney Care, extending the partnership to earlier-stage disease.
peer_disclosureEcuador's IESS said it disbursed USD 111.8 million to external dialysis providers between December 2025 and August 2026, cutting accumulated obligations by 45% and leaving USD 136.2 million outstanding, with DaVita Ecuador among providers awaiting payment.
peer_disclosureThe Peterson Health Technology Institute published a Sept 15, 2026 report finding virtual chronic kidney disease solutions, including DaVita Integrated Kidney Care and seven other vendors, show no evidence of slowing CKD progression or materially cutting healthcare spending.
litigation_outcomeDaVita agreed to a US$15 million settlement resolving claims tied to a prior data breach affecting the company.